The Latest

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    After a record run, fewer biotechs are going public. Here’s how they’re performing.

    Adlai Nortye’s IPO is the 16th for a biotechnology company this year, and raised a smaller amount than it had pitched in early August.

    Updated Sept. 11, 2023
  • Doctors working in lab
    Image attribution tooltip

    Anthony Musmanno

    Image attribution tooltip
    Sponsored by Viatris

    Driving innovation to benefit people living with MS

    A holistic approach to R&D is key to support MS patients throughout their treatment journey.

  • A blurred photo of an empty laboratory
    Image attribution tooltip
    Ozankutsal via Getty Images
    Image attribution tooltip

    PTC to lay off more staff following drug setback in Europe

    The biotech is expanding cuts it announced a few months ago after the EMA decided against renewing a conditional clearance for its drug Translarna.

  • A backlit Karuna Therapeutics sign on a teal wall sits behind a white marble reception desk
    Image attribution tooltip
    Permission granted by Karuna Therapeutics
    Image attribution tooltip

    Karuna submits schizophrenia drug for US approval

    The drug’s success in two late-stage clinical trials has buoyed Karuna to a market valuation exceeding $6 billion. 

  • Colorized scanning electron micrograph of a VERO E6 cell heavily infected with SARS-COV-2 virus particles, isolated from a patient sample.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip

    Gritstone wins ‘Project NextGen’ funding to run head-to-head COVID vaccine study

    In a note to clients, Evercore ISI analyst Jonathan Miller described the Project NextGen contract for Gritstone as “certainly a nice signal of continued government support for COVID research.”

  • A person wearing a blue glove holds a test tube with red liquid
    Image attribution tooltip
    Dmitry Belyaev via Getty Images
    Image attribution tooltip

    Harbinger Health raises $140M to study blood-based cancer screening test

    The test developer will use the Series B funding to complete a 10,000-person clinical trial ahead of a planned launch in 2025.

  • An illustration for BioPharma Dive's deals database
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive

    Biotech M&A is picking back up. Here are the latest deals.

    While Alfasigma’s bid for Intercept comes at an 82% premium to Monday’s close, the proposed $19 per share price is well below what the stock was worth a few years ago. 

    Updated Sept. 26, 2023
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche bets on Ionis RNA medicines with neuroscience deal

    The Swiss drugmaker is restocking its pipeline by buying into preclinical Ionis medicines for Alzheimer’s and Huntington’s diseases.

  • Jynneos Bavarian Nordic vaccine monkeypox
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip
    Q&A

    Inside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant

    Despite the company's recent Phase 3 setbacks in RSV and COVID, CEO Paul Chaplin sees a path forward for the Danish biotech in the travel vaccine market.

  • ProQR sale of eye drugs comes undone over employment contracts

    Laboratoires Théa terminated its planned purchase of ProQR’s sepofarsen after certain ProQR personnel opted against working for the French company.

  • A man in business attire stands for a photo.
    Image attribution tooltip
    Permission granted by John Tsai
    Image attribution tooltip

    Former Novartis executive Tsai to lead UK heart drug startup

    John Tsai, previously Novartis’ chief medical officer, has been named CEO of Forcefield Therapeutics, an 18-month-old biotech that recently licensed AAV technology from Freeline Therapeutics.

  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Immunovant data show potential for autoimmune disease drug

    Much anticipated clinical trial data for Immunovant’s experimental FcRn inhibitor could catalyze business development decisions for its parent, Roivant Sciences.

  • A flag with the Novo Nordisk logo.
    Image attribution tooltip
    Novo Nordisk
    Image attribution tooltip

    Novo Nordisk, Evotec partner in metabolic disease drug discovery pact

    Hunting for more metabolic disease drugs, Novo plans to work with Evotec to shape early academic research into new development programs.

  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis radiopharmaceutical drug succeeds in first-line gut cancer study

    Novartis has made a large investment in targeted radiotherapies, sparking competition from fellow pharma companies and young biotechs.

  • Exterior of FDA headquarters
    Image attribution tooltip
    Courtesy of U.S. Food and Drug Administration
    Image attribution tooltip
    ALS drug development

    FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show

    A panel of expert FDA advisers is meeting today to discuss the treatment, and whether Brainstorm’s data provide “substantial evidence” of its effectiveness.

  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Eisai’s Alzheimer’s drug Leqembi approved in Japan

    Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.

  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Latest trial win supports expanded use of Bristol Myers’ Opdivo in lung cancer

    The drug, which is already cleared as a neoadjuvant lung cancer treatment, could better compete with Merck’s Keytruda if it gains approval in the adjuvant setting for non-small cell tumors.

  • A photo of a Seattle Genetics laboratory
    Image attribution tooltip
    Permission granted by Seagen
    Image attribution tooltip

    Seagen’s cancer drug succeeds in ‘must-win’ trial

    Compared to chemotherapy, a combination of Seagen’s Padcev and Merck’s Keytruda was significantly better at keeping bladder cancer patients alive longer and their disease from progressing.

  • Image attribution tooltip
    Jacob Bell / BioPharma Dive
    Image attribution tooltip

    AstraZeneca and Daiichi’s next cancer medicine scores in breast tumors

    Results show that the medicine helped patients who progressed on earlier-line treatments live longer than those receiving chemotherapy without their disease getting worse, according to a Friday announcement.

  • A photo of a sign showing the Food and Drug Administration logo
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Intarcia’s diabetes drug-device combo voted down again by FDA panel

    The 19-member advisory committee unanimously voted against Intarcia in the review, citing cardiovascular and kidney safety concerns.

    FDA
  • Insulin activates glucose transport into a cell by binding to insulin receptors - stock photo
    Image attribution tooltip
    selvanegra via Getty Images
    Image attribution tooltip

    Cell therapy developer closes funding round to support diabetes program

    More than $50 million in venture funding has now gone into Seraxis, which is among a series of biotechs trying to fundamentally alter diabetes treatment.

  • A man looks at a glass test tube in a lab, with beakers and additional tubes on a surface in front of him. Overlaid on the image are strands of double-helix DNA and chemistry diagrams.
    Image attribution tooltip
    metamorworks via Getty Images
    Image attribution tooltip

    Novo Nordisk parent backs cell therapy manufacturing facility

    The Novo Nordisk Foundation’s planned manufacturing facility will help both private companies and academic researchers develop new cell therapies.

  • A Genentech sign in front of its headquarters in South San Francisco, California.
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Genentech takes up a deal to make ‘molecular glue’ drugs

    Targeted protein degradation has emerged as one of the more competitive areas of pharmaceutical research in recent years as scientists develop new ways to reach difficult-to-drug targets.

    Updated Sept. 20, 2023
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    MadamLead via Getty Images
    Image attribution tooltip

    Roche’s Genentech bets on radiopharmaceuticals in partnership with PeptiDream

    The new deal expands on a yearslong partnership between the two drug developers to advance targeted radioisotopes for certain cancers.

  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Taysha drops lead gene therapy following FDA feedback

    Additional studies proposed by the FDA would be too challenging, according to Taysha, which simultaneously announced that its partner Astellas has declined to pick up an option for the therapy, called TSHA-120.

  • Exterior of FDA headquarters
    Image attribution tooltip
    Courtesy of U.S. Food and Drug Administration
    Image attribution tooltip

    Alvotech gets new FDA review for Humira biosimilar

    The regulator has twice rejected Alvotech’s copycat drug due to manufacturing issues with a plant in Europe.